Amy Baxter is a staff reporter for PharmaVoice. With a strong background in B2B healthcare, she has extensively covered pharmaceutical manufacturing, regulation, and healthcare administration, while also delving into public health topics. Amy's work has been featured in notable publications such as Environmental Leader, BioPharma Dive, and Sailing World Inc.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Amy Baxter's coverage is heavily focused on energy and sustainability, with a strong emphasis on industry developments and corporate announcements. To effectively reach out to her, provide newsworthy updates from the renewable energy sector, innovative sustainable solutions or breakthroughs in technology related to climate change. Expert commentary from professionals directly involved in these areas will likely catch her attention.
Considering that Amy's focus is largely based around official statements and private sector announcements, providing exclusive insights or data-backed stories about emerging trends or significant advancements within the energy and sustainability sectors could be particularly compelling for her.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Novo Nordisk and Eli Lilly’s quarterly earnings revealed shifting dynamics in the lucrative obesity space.
The newly announced program targeting domestic manufacturing is the latest Trump administration move to ramp up drugmaking in the U.S.
By: Amy Baxter
Copycat weight loss drugs were supposed to be pulled from the market, but pharmacies have found a loophole.
RFK Jr. has his sights set on increasing oversight and enforcement against pharmas that run afoul of ad laws.
RFK Jr. has his sights set on increasing oversight and enforcement against drugmakers that run afoul of advertising laws.
By: Amy Baxter
Faster review times will leave drugmakers vulnerable to litigation, while new Trump administration priorities add more uncertainty in the drug approval process.
Newcomers looking for a way into the obesity space are developing unique methods to snag market share.
